New arthritis drug enters human testing after surprising early results
NCT ID NCT07433335
Summary
This early-stage study is testing a new drug called SR-878 in people with rheumatoid arthritis to see if it's safe and to find the right dose for future research. The drug works differently than current treatments by targeting a protein involved in inflammation. Researchers will enroll 27 adults with active arthritis who haven't responded well to standard medications, giving them a single infusion and monitoring them closely for about 16 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SciRhom clinical trial site
Tbilisi, Georgia
-
SciRhom clinical trial site
Chisinau, Moldova
-
SciRhom clinical trial site
Bucharest, Romania
-
SciRhom clinical trial site
Cluj-Napoca, Romania
Conditions
Explore the condition pages connected to this study.